CATALANO, ROSA
CATALANO, ROSA
Dipartimento di Scienze Cliniche e di Comunità
Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma
2025 E. Nozza, E. Emanuela, G. Di Muro, S. Di Bari, R. Catalano, G. Lopez, V. Vaira, A.M. Barbieri, G. Marra, M. Federica, T. Donatella, M. Battistin, Di Dalmazi Guido, S. Palmieri, F. Emanuele, G. Mantovani, E.M. Peverelli
Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas
2025 R. Catalano, E. Nozza, B. Altieri, E. Esposito, G.A. Croci, A.M. Barbieri, D. Treppiedi, S. Di Bari, O. Kimpel, M. Detomas, M. Tamburello, M.P. Schauer, S. Herterich, A. Angelousi, M. Luconi, L. Canu, G. Nesi, C. Hantel, S. Sigala, L. Landwehr, G. Di Dalmazi, E. Cassinotti, L. Baldari, S. Palmieri, A. Mangone, E. Ferrante, C.L. Ronchi, G. Mantovani, E. Peverelli
Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas
2025 E. Esposito, G. Marra, R. Catalano, S. Maioli, E. Nozza, A.M. Barbieri, C. Hantel, G. Di Dalmazi, S. Sigala, J. Geginat, E. Cassinotti, L. Baldari, S. Palmieri, A. Mangone, A. Berruti, E. Ferrante, G. Mantovani, E. Peverelli
The Cytoskeleton in Adrenal Physiology and Tumours: Functional Roles and Emerging Molecular Targets
2025 R. Catalano, E. Nozza, E. Esposito, S. Di Bari, G. Mantovani, E. Peverelli
AZD1775: effect of monotherapy or EDP-M combination in the treatment of ACC preclinical models
2025 E. Nozza, R. Catalano, G. Di Muro, S. Di Bari, G. Lopez, G. Marra, E. Esposito, F. Mangili, D. Treppiedi, M. Battistin, G. Mantovani, E. Peverelli
The novel SST3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells
2024 G. Di Muro, R. Catalano, D. Treppiedi, A.M. Barbieri, F. Mangili, G. Marra, S. Di Bari, E. Esposito, E. Nozza, A. Lania, M. Locatelli, D. Modena, C. Steinkuhler, E. Peverelli, G. Mantovani
The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells
2024 G. Di Muro, R. Catalano, D. Treppiedi, A.M. Barbieri, F. Mangili, G. Marra, S. Di Bari, E. Esposito, E. Nozza, A.G. Lania, E. Ferrante, M. Locatelli, D. Modena, C. Steinkuhler, E. Peverelli, G. Mantovani
Sphingosine kinase 1 inhibitor safingol as a new possible therapeutic strategy for adrenocortical carcinoma
2024 E. Nozza, R. Catalano, E. Esposito, S. Palmieri, B. Altieri, L. Landwehr, H. Constanze, S. Sigala, E. Ferrante, G. Mantovani, E. Peverelli
Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas
2024 E. Esposito/, R. Catalano, E. Nozza, G. Marra, S. Maioli, G. Dimuro, A.M. Barbieri, H. Constanze, G. Didalmazi, J.E. Geginat, E. Cassinotti, L. Baldari, S. Palmieri, A. Mangone, E. Ferrante, G. Mantovani, E. Peverelli
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
2023 G. Di Muro, F. Mangili, E. Esposito, A.M. Barbieri, R. Catalano, D. Treppiedi, G. Marra, E. Nozza, A.G.A. Lania, E. Ferrante, M. Locatelli, M. Arosio, E. Peverelli, G. Mantovani
High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study
2023 R. Catalano, B. Altieri, A. Angelousi, M. Arosio, F. Bravi, L. Canu, G.A. Croci, M. Detomas, E. Esposito, E. Ferrante, S. Ferrero, C.T. Fuss, G. Kaltsas, O. Kimpel, L. Landwehr, M. Luconi, V. Morelli, G. Nesi, E. Nozza, S. Sbiera, A.L. Serban, C.L. Ronchi, G. Mantovani, E. Peverelli
IGF2R: a new player in the insulin-like growth factor 2 (IGF2) pathway sustaining adrenocortical carcinoma cells growth
2023 E. Nozza, R. Catalano, E. Esposito, A.M. Barbieri, G. Marra, D. Treppiedi, G. Di Muro, F. Mangili, H. Constanze, S. Sigala, S. Palmieri, S. Frigerio, E. Ferrante, M. Arosio, G. Mantovani, E. Peverelli
Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer
2022 D. Treppiedi, R. Catalano, F. Mangili, G. Mantovani, E. Peverelli
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
2022 D. Treppiedi, G. Marra, G. DI MURO, E. Esposito, A.M. Barbieri, R. Catalano, F. Mangili, F. Bravi, M. Locatelli, A. Gerardo Lania, E. Ferrante, R. Indirli, E. Nozza, F. Arlati, A. Spada, M. Arosio, G. Mantovani, E.M. Peverelli
Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation
2022 D. Treppiedi, G. Marra, G. Di Muro, R. Catalano, F. Mangili, E. Esposito, D. Calebiro, M. Arosio, E. Peverelli, G. Mantovani
TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
2022 D. Treppiedi, G. Marra, G. Di Muro, R. Catalano, F. Mangili, E. Esposito, A.M. Barbieri, M. Arosio, G. Mantovani, E. Peverelli
Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior
2022 A. Spada, G. Mantovani, A. Lania, D. Treppiedi, F. Mangili, R. Catalano, G. Carosi, E. Sala, E. Peverelli
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
2022 F. Mangili, E. Esposito, D. Treppiedi, R. Catalano, G. Marra, G. Di Muro, A.M. Barbieri, M. Locatelli, A.G. Lania, A. Mangone, A. Spada, M. Arosio, E. Peverelli, G. Mantovani
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells
2021 R. Catalano, E. Giardino, D. Treppiedi, F. Mangili, V. Morelli, F.M. Elli, A.L. Serban, M. Luconi, M. Mannelli, A. Spada, M. Arosio, G. Mantovani, E. Peverelli
β-arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors
2021 F. Mangili, E. Giardino, D. Treppiedi, A.M. Barbieri, R. Catalano, M. Locatelli, A.G. Lania, A. Spada, M. Arosio, G. Mantovani, E. Peverelli